Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 dose-escalation study of OPB-171775 in advanced or metastatic solid tumors
jRCT2031200206Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Nov 2020
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MTX240 in Nonhematologic neoplasms, sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Dose-limiting toxicity. Started Nov 2020; status: completed.
02
Drugs
MTX240
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031200206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200206.